Many patients with Hashimoto's disease struggle with weight management and metabolic challenges, leading to questions about whether GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) might help
November 2025 studies confirm both reduce cardiovascular events by up to 18%, regardless of weight loss amount
Future Directions in Incretin Therapy The success of oral semaglutide has sparked interest in additional oral incretin therapies and combination drugs
Akkermansia can do this by stimulating intestinal L cells to secrete GLP-1
For the CY 2026 OPPS, we proposed to continue to remove claim lines with modifier PN from the ratesetting process
Common combinations include metabolic support peptides like MOTS-c for mitochondrial enhancement, cellular energy peptides like 5-Amino-1MQ, or even growth hormone secretagogues if both fat-specific and broader anabolic effects are desired